Chemicals · Founded 1960 · www.kanoriachem.com · BSE 506525 · NSE KANORIA CHEM · ISIN INE138C01024
No Notes Added Yet
Business
Kanoria Chemicals & Industries Ltd. (KANORICHEM) is an Indian chemical manufacturing company primarily engaged in the production of various industrial and specialty chemicals. Its core business revolves around manufacturing and selling products like Formaldehyde, Hexamethylenetetramine (HMTA), Pentaerythritol, Sodium Formate, and Acetaldehyde. These chemicals serve as crucial raw materials and intermediates for a wide range of end-user industries including plastics, synthetic resins, agrochemicals, pharmaceuticals, dyes, leather, textiles, paints, and construction. The company operates on a B2B model, supplying its products to other industrial consumers. It makes money by producing these chemicals efficiently and selling them to a diverse customer base across various industrial sectors.
Revenue Mix
Kanoria Chemicals & Industries Ltd. primarily operates within a single 'Chemicals' segment. Within this, its revenue is generated from the sale of its key product groups:
Formaldehyde & Derivatives: Includes Formaldehyde and Hexamethylenetetramine (HMTA).
Performance Chemicals: Includes Pentaerythritol and Sodium Formate.
Basic Chemicals: Includes Acetaldehyde.
Specific revenue contributions from each product group are typically not disclosed granularly in public reports, but these product categories represent their core revenue streams.
Industry
KANORICHEM operates within the Indian Chemicals sector, specifically in the manufacturing of basic and specialty chemicals. The industry is diverse, encompassing a wide array of products serving numerous end-user sectors. For basic chemicals like Formaldehyde and Acetaldehyde, the industry can be price-sensitive and competitive, with both large diversified players and smaller, specialized manufacturers. In products like HMTA and Pentaerythritol, Kanoria Chemicals holds a significant position, often being among the largest producers in India, indicating a strong market share in these specific niches. The Indian chemical industry is characterized by increasing domestic demand, backward integration efforts, and a push towards specialty chemicals.
MOAT
Kanoria Chemicals' competitive advantages are primarily derived from:
Scale and Cost Efficiency: For its core products like Formaldehyde, HMTA, and Pentaerythritol, the company has established significant production capacities, which can lead to economies of scale and cost efficiencies in manufacturing processes, providing a pricing edge in commodity-like markets.
Established Customer Relationships: A long operational history has allowed them to build strong, enduring relationships with key industrial customers across various sectors, ensuring consistent demand.
Technical Expertise & Reliability: Consistent product quality and reliable supply are crucial for industrial chemical buyers, where the company has built a reputation over decades.
Strategic Plant Locations: Having manufacturing facilities strategically located can provide logistics advantages in serving key industrial hubs.
Growth Drivers
Key factors that can drive growth for Kanoria Chemicals over the next 3-5 years include:
Domestic Industrial Growth: Robust growth in end-user industries such as housing, construction, automotive, pharmaceuticals, agrochemicals, and textiles in India will directly drive demand for the company's chemicals.
Capacity Expansion: Ongoing and planned capital expenditure projects to increase production capacities for key products like Formaldehyde and Pentaerythritol are expected to boost sales volumes.
Product Portfolio Enhancement: Potential for diversification into higher-value specialty chemicals or new derivatives that cater to evolving industrial needs.
Exports: Leveraging competitive production costs to increase exports to global markets, thereby expanding its customer base beyond India.
Backward Integration: Any efforts towards securing raw material supplies or reducing input costs through backward integration could enhance profitability and competitiveness.
Risks
Raw Material Price Volatility: Significant fluctuations in the prices of key raw materials (e.g., Methanol for Formaldehyde, Acetaldehyde) can severely impact production costs and profit margins.
Intense Competition: The chemical industry is competitive, and pressure from domestic and international players can lead to pricing pressures and margin erosion.
Environmental Regulations: Stringent environmental norms and compliance costs can increase operating expenses, require significant capital investments, or even lead to production curtailments.
Demand Cyclicality: Demand for its products is linked to the performance of various industrial sectors, which can be cyclical, leading to volatility in sales and profitability.
Foreign Exchange Fluctuations: Given potential imports of raw materials or exports of finished goods, currency rate movements can impact profitability.
Operational Risks: Risks associated with chemical manufacturing, such as plant breakdowns, accidents, or supply chain disruptions.
Management & Ownership
Kanoria Chemicals & Industries Ltd. is promoted by the Kanoria family, which has a long-standing presence in the Indian industrial landscape. The promoters generally hold a significant stake in the company, reflecting their long-term commitment and control. The management team includes professionals with experience in the chemical industry. Corporate governance practices typically adhere to Indian regulatory standards. Promoter-driven companies in India often exhibit a focus on long-term sustainability and growth, often through internal accruals and strategic expansions.
Outlook
Kanoria Chemicals is a well-established player in critical segments of the Indian chemical industry, benefiting from the country's overall industrial growth trajectory. Its strong market position in specific products like HMTA and Pentaerythritol, coupled with ongoing capacity expansions, positions it to capture rising domestic demand. However, the company remains susceptible to the inherent cyclicality and volatility of the chemical sector, particularly concerning raw material price fluctuations and intense competition. Its future performance will largely depend on successful execution of expansion projects, effective raw material sourcing strategies, and its ability to navigate the evolving regulatory and competitive landscape while potentially diversifying into higher-margin products.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 361 | 384 | 177 | 180 | 214 | 201 | 210 | 266 | 304 | 460 |
| Other Income | 1 | 1 | 12 | 1 | 3 | 1 | 12 | 2 | 7 | 7 |
| Total Income | 362 | 385 | 188 | 181 | 217 | 202 | 222 | 268 | 312 | 467 |
| Total Expenditure | 333 | 382 | 176 | 165 | 201 | 183 | 204 | 246 | 277 | 415 |
| Operating Profit | 29 | 3 | 12 | 16 | 15 | 19 | 19 | 22 | 34 | 52 |
| Interest | 12 | 11 | 8 | 8 | 7 | 7 | 9 | 8 | 8 | 7 |
| Depreciation | 15 | 15 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -29 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | -23 | -4 | -0 | -30 | 3 | 1 | 6 | 17 | 35 |
| Provision for Tax | 18 | 1 | 7 | 2 | 2 | 3 | 3 | 2 | -15 | 9 |
| Profit After Tax | -15 | -24 | -11 | -2 | -32 | -1 | -2 | 4 | 32 | 26 |
| Adjustments | 6 | 7 | -3 | -15 | -5 | -7 | 96 | 0 | 0 | 0 |
| Profit After Adjustments | -9 | -17 | -14 | -17 | -36 | -8 | 93 | 4 | 32 | 26 |
| Adjusted Earnings Per Share | -2.1 | -3.8 | -3.2 | -3.8 | -8.3 | -1.8 | 21.4 | 0.8 | 7.2 | 6 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 565 | 702 | 837 | 1072 | 1005 | 1095 | 1369 | 1578 | 1475 | 754 | 981 | 1240 |
| Other Income | 20 | 26 | 45 | 13 | 24 | 16 | 29 | 15 | 19 | 18 | 25 | 28 |
| Total Income | 586 | 728 | 882 | 1084 | 1029 | 1111 | 1398 | 1593 | 1494 | 772 | 1006 | 1269 |
| Total Expenditure | 539 | 676 | 802 | 1008 | 979 | 1005 | 1301 | 1511 | 1423 | 723 | 912 | 1142 |
| Operating Profit | 47 | 52 | 80 | 76 | 50 | 106 | 97 | 83 | 72 | 49 | 94 | 127 |
| Interest | 14 | 20 | 24 | 36 | 37 | 32 | 27 | 36 | 43 | 31 | 32 | 32 |
| Depreciation | 34 | 45 | 47 | 49 | 56 | 58 | 57 | 59 | 59 | 32 | 35 | 36 |
| Exceptional Income / Expenses | 0 | -18 | 0 | -5 | 0 | -4 | 0 | 0 | 0 | -29 | 0 | 0 |
| Profit Before Tax | -1 | -32 | 10 | -15 | -43 | 11 | 13 | -12 | -31 | -43 | 27 | 59 |
| Provision for Tax | 6 | -8 | -2 | 5 | -11 | -5 | 11 | 1 | 21 | 11 | -6 | -1 |
| Profit After Tax | -7 | -24 | 12 | -19 | -32 | 16 | 2 | -13 | -52 | -54 | 32 | 60 |
| Adjustments | 0 | 9 | 2 | 5 | 6 | -1 | 5 | 4 | 13 | -29 | 88 | 96 |
| Profit After Adjustments | -7 | -15 | 14 | -15 | -26 | 15 | 7 | -9 | -38 | -84 | 121 | 155 |
| Adjusted Earnings Per Share | -1.6 | -3.4 | 3.2 | -3.4 | -5.9 | 3.3 | 1.6 | -2 | -8.8 | -19.1 | 27.6 | 35.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | -15% | -2% | 6% |
| Operating Profit CAGR | 92% | 4% | -2% | 7% |
| PAT CAGR | 0% | 0% | 15% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 110% | 12% | -2% | 7% |
| ROE Average | 6% | -4% | -3% | -2% |
| ROCE Average | 6% | 2% | 2% | 2% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 603 | 580 | 588 | 598 | 569 | 587 | 599 | 605 | 601 | 521 | 573 |
| Minority's Interest | 18 | 9 | 6 | 16 | 12 | 8 | 3 | 2 | 16 | -10 | 0 |
| Borrowings | 266 | 266 | 260 | 258 | 338 | 345 | 343 | 320 | 297 | 344 | 183 |
| Other Non-Current Liabilities | 78 | 64 | 59 | 62 | 51 | 46 | 49 | 46 | 67 | 73 | 52 |
| Total Current Liabilities | 259 | 291 | 365 | 466 | 404 | 375 | 409 | 509 | 509 | 571 | 309 |
| Total Liabilities | 1225 | 1209 | 1278 | 1401 | 1374 | 1362 | 1403 | 1481 | 1490 | 1498 | 1117 |
| Fixed Assets | 512 | 743 | 800 | 850 | 894 | 864 | 863 | 882 | 850 | 865 | 727 |
| Other Non-Current Assets | 381 | 129 | 82 | 95 | 45 | 39 | 33 | 27 | 78 | 67 | 105 |
| Total Current Assets | 331 | 338 | 395 | 456 | 434 | 459 | 504 | 569 | 556 | 560 | 279 |
| Total Assets | 1225 | 1209 | 1278 | 1401 | 1374 | 1362 | 1403 | 1481 | 1490 | 1498 | 1117 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 33 | 18 | 16 | 11 | 19 | 36 | 32 | 19 | 19 | 12 | 4 |
| Cash Flow from Operating Activities | 12 | 30 | 27 | 22 | 31 | 82 | 83 | 26 | 38 | 17 | 71 |
| Cash Flow from Investing Activities | -109 | 7 | -21 | -86 | -3 | -12 | -43 | -29 | -50 | -20 | -8 |
| Cash Flow from Financing Activities | 82 | -39 | -11 | 73 | -11 | -75 | -53 | 3 | 5 | -5 | -58 |
| Net Cash Inflow / Outflow | -15 | -2 | -5 | 8 | 17 | -4 | -13 | -0 | -8 | -8 | 6 |
| Closing Cash & Cash Equivalent | 18 | 16 | 11 | 19 | 36 | 32 | 19 | 19 | 11 | 4 | 10 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1.65 | -3.38 | 3.22 | -3.42 | -5.9 | 3.32 | 1.56 | -2.01 | -8.79 | -19.13 | 27.64 |
| CEPS(Rs) | 6.21 | 4.98 | 13.32 | 6.86 | 5.61 | 16.94 | 13.6 | 10.54 | 1.74 | -5.17 | 15.46 |
| DPS(Rs) | 1.5 | 1.5 | 1.5 | 0.75 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 137.97 | 132.75 | 134.56 | 136.97 | 130.11 | 134.4 | 137.09 | 138.56 | 137.61 | 119.2 | 131.12 |
| Core EBITDA Margin(%) | 4.43 | 3.59 | 4.1 | 5.92 | 2.58 | 8.17 | 4.98 | 4.3 | 3.54 | 4.15 | 7.05 |
| EBIT Margin(%) | 2.1 | -1.56 | 3.96 | 1.96 | -0.61 | 4 | 2.91 | 1.51 | 0.83 | -1.59 | 5.97 |
| Pre Tax Margin(%) | -0.23 | -4.32 | 1.14 | -1.4 | -4.26 | 1.04 | 0.96 | -0.77 | -2.09 | -5.71 | 2.71 |
| PAT Margin (%) | -1.2 | -3.23 | 1.37 | -1.82 | -3.14 | 1.46 | 0.16 | -0.82 | -3.51 | -7.22 | 3.3 |
| Cash Profit Margin (%) | 4.54 | 2.97 | 6.89 | 2.8 | 2.44 | 6.76 | 4.34 | 2.92 | 0.52 | -2.99 | 6.88 |
| ROA(%) | -0.65 | -1.95 | 0.93 | -1.46 | -2.27 | 1.17 | 0.16 | -0.89 | -3.48 | -3.65 | 2.48 |
| ROE(%) | -1.31 | -4.01 | 1.98 | -3.29 | -5.41 | 2.77 | 0.38 | -2.14 | -8.57 | -9.71 | 5.92 |
| ROCE(%) | 1.35 | -1.13 | 3.3 | 1.97 | -0.55 | 4 | 3.71 | 2.18 | 1.1 | -1.08 | 5.93 |
| Receivable days | 49.58 | 50.27 | 54.45 | 48.25 | 52.61 | 57.86 | 50.18 | 42.66 | 47.17 | 102.42 | 69.04 |
| Inventory Days | 47.68 | 45.6 | 52.77 | 56.48 | 67.51 | 58.01 | 56.06 | 61.45 | 69.62 | 128.51 | 65.5 |
| Payable days | 59.15 | 59.86 | 71.53 | 69.54 | 82.22 | 78.42 | 69.37 | 71.98 | 83.26 | 153.8 | 93.94 |
| PER(x) | 0 | 0 | 20.43 | 0 | 0 | 27.42 | 87.12 | 0 | 0 | 0 | 2.03 |
| Price/Book(x) | 0.39 | 0.52 | 0.49 | 0.46 | 0.18 | 0.68 | 0.99 | 0.77 | 0.77 | 0.63 | 0.43 |
| Dividend Yield(%) | 2.8 | 2.16 | 2.28 | 1.2 | 0 | 0 | 0.73 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.08 | 0.95 | 0.81 | 0.69 | 0.59 | 0.78 | 0.76 | 0.6 | 0.65 | 1.21 | 0.53 |
| EV/Core EBITDA(x) | 12.97 | 12.74 | 8.5 | 9.69 | 11.96 | 8.08 | 10.74 | 11.49 | 13.36 | 18.45 | 5.55 |
| Net Sales Growth(%) | 6.44 | 24.22 | 19.19 | 28.08 | -6.25 | 8.97 | 25.05 | 15.29 | -6.55 | -48.86 | 30.11 |
| EBIT Growth(%) | -42.47 | -191.42 | 391.38 | -37.07 | -129.05 | 815.97 | -8.98 | -40.33 | -48.56 | -198.13 | 588.7 |
| PAT Growth(%) | -158.41 | -229.4 | 148.82 | -268.53 | -61.83 | 150.68 | -86.03 | -676.94 | -301.38 | -5.37 | 159.44 |
| EPS Growth(%) | -158.41 | -105.41 | 195.08 | -206.24 | -72.8 | 156.31 | -53 | -228.42 | -338.02 | -117.72 | 244.47 |
| Debt/Equity(x) | 0.71 | 0.72 | 0.75 | 0.85 | 0.95 | 0.83 | 0.79 | 0.84 | 0.84 | 1.14 | 0.51 |
| Current Ratio(x) | 1.28 | 1.16 | 1.08 | 0.98 | 1.07 | 1.22 | 1.23 | 1.12 | 1.09 | 0.98 | 0.9 |
| Quick Ratio(x) | 0.97 | 0.81 | 0.7 | 0.57 | 0.62 | 0.78 | 0.61 | 0.57 | 0.53 | 0.55 | 0.56 |
| Interest Cover(x) | 0.9 | -0.57 | 1.4 | 0.58 | -0.17 | 1.35 | 1.49 | 0.66 | 0.28 | -0.39 | 1.83 |
| Total Debt/Mcap(x) | 1.83 | 1.37 | 1.53 | 1.87 | 5.14 | 1.23 | 0.79 | 1.09 | 1.1 | 1.82 | 1.18 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 |
| FII | 0.16 | 0.01 | 0.01 | 0.02 | 0.01 | 0 | 0 | 0 | 0.01 | 0.03 |
| DII | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Public | 25.33 | 25.48 | 25.48 | 25.47 | 25.48 | 25.49 | 25.49 | 25.49 | 25.48 | 25.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +30% | -15% | -2% | +6% |
| Operating Profit CAGR | +92% | +4% | -2% | +7% |
| PAT CAGR | — | — | +15% | — |
| Share Price CAGR | +110% | +12% | -2% | +7% |
| ROE Average | +6% | -4% | -3% | -2% |
| ROCE Average | +6% | +2% | +2% | +2% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 | 74.4 |
| FII | 0.16 | 0.01 | 0.01 | 0.02 | 0.01 | 0 | 0 | 0 | 0.01 | 0.03 |
| DII | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Public | 25.33 | 25.48 | 25.48 | 25.47 | 25.48 | 25.49 | 25.49 | 25.49 | 25.48 | 25.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.